When was DNAnexus founded?

DNAnexus was founded in 2009 and raised its 1st funding round within a year of its incorporation.

Where is DNAnexus located?

DNAnexus is headquartered in Mountain View, United States. It is registered at Mountain View, California.

How many employees does DNAnexus have?

As of Sep 30, 2026, the latest employee count at DNAnexus is 279.

Is DNAnexus a funded company?

DNAnexus is a funded company, having raised a total of $473M across 10 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 28, 2009.

How much is DNAnexus worth?

The latest valuation of DNAnexus is $***** as of Mar 08, 2022.

When was the latest funding round of DNAnexus?

DNAnexus' latest funding was a $***** Series H round on Mar 08, 2022, with participation from 6 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.71B in funding in 2026 to date.

Where does DNAnexus rank among its competitors?

DNAnexus ranks 34th amongst 2909 active competitors, of which 920 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of DNAnexus?

DNAnexus' top competitors include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Among them, Immuneel secured the most recent funding round in June, 2026.

DNAnexus - 2026 Company Profile, Team, Funding & Competitors

DNAnexus is a series H company based in Mountain View (United States), founded in 2009 by Arend Sidow, Serafim Batzoglou and Andreas Sundquist. It operates as a Provider of cloud-based genome informatics & data management platform. DNAnexus has raised $473M in funding from investors like Google Ventures, TPG and First Round Capital, with a current valuation of $*****. The company has 2909 active competitors, including 920 funded and 643 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Tango Therapeutics and Elicio.

Company Details

DNAnexus provides cloud-based genome informatics and data management tools for enterprises and organizations that are engaged in the development and delivery of genomic medicine. The company’s platform enables the companies to analyze raw sequencing data; integrate genomic data with clinical and other phenotypic data, and collaborate seamlessly.

Website: www.dnanexus.com/
Social
Email ID: *****@dnanexus.com
Registered Address: Mountain View, California

Key Metrics

Founded Year

2009

Location

Mountain View, United States

Stage

Series H

Total Funding

$473M in 10 rounds

Latest Funding Round

Series H, Mar 08, 2022, $*****

Post Money Valuation

$***** as on Mar 08, 2022

Investors

Google Ventures & 23 more

Ranked

34^th among 2909 active competitors

Employee Count

279 as on Sep 30, 2026

Similar Companies

Fabric Genomics & 546 more

View DNAnexus' full profile

DNAnexus is associated with 7 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
DNA MEDICAL GROUP s.r.o. CIN: 19900376 , Czech Republic, Active	Nov 07, 2023	-	-
D.N.A Brand s.r.o. CIN: 19178930 , Czech Republic, Active	Mar 23, 2023	-	-
BUSINESS DNA s.r.o. CIN: 07846991 , Czech Republic, Active	Jan 29, 2019	-	-
DNA MARKETING s.r.o. CIN: 07846975 , Czech Republic, Active	Jan 30, 2019	-	-
DNAnexus Czech Republic s.r.o. CIN: 07747365 , Czech Republic, Active	Dec 20, 2018	-	-
DNAX s.r.o. CIN: 03738850 , Czech Republic, Active	Jan 23, 2015	-	-
DNANEXUS, INC. CIN: 264233063 , United States, Active	Dec 31, 1999	-	147 (As on Dec 31, 2024)	-

DNAnexus has raised a total funding of $473M over 10 rounds. Its first funding round was on Jul 28, 2009. Its latest funding round was a Series H round on Mar 08, 2022 for $*****. 6 investors participated in its latest round. DNAnexus has 24 institutional investors.

Here is the list of recent funding rounds of DNAnexus:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 08, 2022	4296134	Series H	3891185	7652972	2524551	1492205
Jun 09, 2020	4525601	Series G	5835118	1489741	1642173	Google Ventures & 4 more
Feb 06, 2019	2546905	Conventional Debt	9275848	4521345	6542372	Innovatus Capital Partners

Access funding benchmarks and valuations. Sign up today!

View details of DNAnexus's funding rounds and investors

The founders of DNAnexus are Arend Sidow, Serafim Batzoglou and Andreas Sundquist. Richard Daly is the CEO of DNAnexus.

Here are the details of DNAnexus' key team members:

Arend Sidow: Co-Founder of DNAnexus and founder of 1 other company.
Contact Info: 1 email address
Serafim Batzoglou: Co-Founder of DNAnexus and founder of 1 other company.
Contact Info: 1 email address
Andreas Sundquist: Former Founder of DNAnexus.
Contact Info: 1 email address
Richard Daly: CEO of DNAnexus. They serve on the board of 1 company.
Contact Info: 1 email address

View details of DNAnexus's Founder profiles and Board Members

DNAnexus' employee count trend

DNAnexus has 279 employees as of Sep 26. Here is DNAnexus's employee count trend over the years:

Uncover DNAnexus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DNAnexus include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Here is the list of Top 10 competitors of DNAnexus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
3rd	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
4th	Fabric Genomics 2009, Oakland (United States), Acquired	AI-based disease diagnosis and genomic analysis tool for providers	$32.8M	UPMC, LDV Partners & 13 others	71/100
5th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
6th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
7th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
8th	Philogen 1996, Sovicille (Italy), Public	Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders	$69.7M	The Equity Club, Novacapital & 3 others	70/100
9th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	70/100
10th	Deciphera 2003, Waltham (United States), Acquired	Developer of type 2 kinase inhibitors for treating cancer	$173M	Redmile Group, New Leaf Venture Partners & 4 others	70/100
34th	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Foresite Capital, Perceptive Advisors & 22 others	67/100